CPC 701

Drug Profile

CPC 701

Latest Information Update: 17 Oct 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Questcor Pharmaceuticals
  • Class Antidementias; Neuroprotectants
  • Mechanism of Action Excitatory amino acid antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neurological disorders

Most Recent Events

  • 13 Oct 2005 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
  • 16 Dec 2003 No development reported - Preclinical for Neurological disorders in USA (unspecified route)
  • 20 Dec 1999 Cypros Pharmaceutical has merged with RiboGene to form Questcor Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top